For Australian Healthcare Professionals
SCAN TO EXPLORE KEY MOMENTS TO BRING UP SHINGRIX VACCINATION
WINTER
MAMMOGRAM
GUT HEALTH
ANNUAL
CHECK
SKIN
HEART PROSTATE
SHINGLES
CHAT
There are many opportunities for you to chat shingles vaccination with your patients aged 50 and over. Where will you start?
Safety 1: In pivotal trials, very common( ≥10 %) solicited local adverse reactions and solicited general adverse events were pain, redness, and swelling at the injection site; and myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms, respectively.
Indication 1: SHINGRIX is indicated for the prevention of herpes zoster( HZ) and post-herpetic neuralgia in: adults 50 years of age or older, and in adults 18 years of age or older at increased risk of HZ. Contraindication 1: Hypersensitivity to the active substances or to any component of the vaccine.
PBS Information: SHINGRIX is listed on the National Immunisation Program( NIP) for Aboriginal and Torres Strait Islander adults aged ≥50 years, for all individuals aged ≥65 years and for adults aged ≥18 years with some immunocompromising medical risk conditions. Refer to NIP schedule or your State or Territory Health department.
Please review Product Information before prescribing. Product Information can be accessed at www. gsk. com. au / shingrix or by scanning the QR code.
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems.
Reference: 1. SHINGRIX Approved Product Information. For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109 GlaxoSmithKline Australia Pty Ltd. ABN 47 100 162 481. Melbourne, VIC. Trade marks are owned by or licensed to the GSK group of companies. © 2025 GSK group of companies or its licensor. PM-AU-SGX-NLTR-250004. Date of approval: July 2025
Recombinant Varicella Zoster Virus glycoprotein E antigen( AS01B adjuvanted vaccine)